TScan designs therapies that reprogram a patient\'s own T cells to recognize and fight their cancer using naturally occurring TCRs that recognize shared cancer targets. The TScan discovery process is a proprietary genome-wide, high-throughput target identification screen, designed to rapidly identify the natural targets of TCRs. TScan is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/24/19 | $48,000,000 | Series B |
Google Ventures Longwood Fund Novartis Institute for Biomedical Research Novartis Venture Funds | undisclosed |
| 01/09/20 | undisclosed | Series B |
Astellas Venture Management Novartis Institute for Biomedical Research Pitango Venture Capital | undisclosed |
| 01/25/21 | $100,000,000 | Series C |
6 Dimensions Capital BlackRock GV Longwood Fund Novartis Venture Funds Pitango Venture Capital RA Capital Management | undisclosed |
